Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
CLPTM1L is a GPI-anchoring pathway component targeted by HCMV
Inbal Kol
*
, Ahmed Rishiq
, Mevaseret Cohen
, Shira Kahlon
, Ophir Pick
, Liat Dassa
, Natan Stein
, Yotam Bar-On
,
Dana G. Wolf
, Einat Seidel
,
Ofer Mandelboim
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'CLPTM1L is a GPI-anchoring pathway component targeted by HCMV'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Neuroscience
Cleft
100%
Transmembrane Protein
100%
Lip
100%
Synapsin I
100%
Human Cytomegalovirus
100%
Palate
100%
Polypeptide
16%
CD59
16%
Glycosylphosphatidylinositol Anchored Protein
16%
Keyphrases
Transmembrane Protein
100%
Human Cytomegalovirus
100%
GPI-anchored Protein (GPI-AP)
100%
Cleft Lip with or without Cleft Palate
100%
MELTF
33%
Immune Regulation
16%
Freeform
16%
Stress Ligands
16%
Normal Development
16%
ULBP3
16%
Immune Recognition
16%
CD59
16%
MHC Class I Polypeptide-related Sequence A
16%
ULBP2
16%
CLPTM1L
16%
GPI Transamidase
16%
CD109
16%
Immunology and Microbiology
Human Cytomegalovirus
100%
Lip
100%
Palate
100%
Infection
33%
Allele
16%
MHC Class I
16%
Immunomodulation
16%
Antigen Recognition
16%
CD59
16%
Biochemistry, Genetics and Molecular Biology
Transmembrane Protein
100%
Synapsin I
100%
Human Cytomegalovirus
100%
Allele
16%
Immunomodulation
16%
Antigen Recognition
16%
MHC Class I Polypeptide-Related Sequence A
16%
CD59
16%
Pharmacology, Toxicology and Pharmaceutical Science
Synapsin I
100%
Human Cytomegalovirus
100%
Cleft Lip Palate
100%
Infection
33%
Polypeptide
16%
Glycosylphosphatidylinositol Anchored Protein
16%
Cadmium 109
16%